VolitionRx Limited (VNRX)
NYSE American · Healthcare · Medical Devices
$0.232−1.28%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $7.0M
- 52-week range
- $0.23 – $13.40
- 52-week change
- −98.15%
- EPS (trailing)
- −$3.75
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $1.7M (+40.04%)
- Net income
- −$23.4M
- Operating margin
- −1258.5%
- Free cash flow
- −$19.8M
From the company’s annual report on SEC EDGAR.
About VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Headquarters: Henderson, United States · 57 employees · volition.com